Comparative, single-dose bioavailability study of two 500 mg clarithromycin tablet formulations in healthy volunteers under fasting condition
Journal
Macedonian Pharmaceutical Bulletin
Date Issued
2019
Author(s)
Kolovcevski Nikola
Labachevski Bojan
Svinarov Dobrin
Abstract
Clarithromycin is a semi-synthetic macrolide antibiotic, chemically 6-0-
methylerythromycin, formulated as immediate-release tablets, extended-release tablets, and
granules for oral suspension.
The objective of this study was to evaluate and compare the relative bioavailability, and
therefore the bioequivalence of Clarithromycin 500 mg test formulation versus a reference Klacid®
forte 500 mg formulation, following a single dose administration under fasting conditions.
The study was a single center, open, single dose, randomized, two-way crossover study in
healthy male volunteers, with a wash-out period of one week between study periods. Twenty-four
male healthy volunteers, aged 18-49 years were included into study. Blood samples for
determination of clarithromycin and 14-OH clarithromycin concentrations were withdrawn at zero
(pre-drug administration), 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 and 36 hours post-drug
administration.
The determination of clarithromycin and 14-OH clarithromycin concentrations in plasma
was performed using validated LC/MS/MS method and internal standardization after liquid/liquid
extraction with methyl t-butyl ether.
The test formulation of clarithromycin, dosed at 500 mg is bioequivalent for primary
clarithromycin and 14-OH clarithromycin parameters (Cmax, AUC0-t and AUC0-∞) to the reference
formulation after a single oral administration of 500 mg clarithromycin. Both medications were
well tolerated with no serious adverse events. Thus, in view of the clinical use, both formulations
are exchangeable without restrictions.
methylerythromycin, formulated as immediate-release tablets, extended-release tablets, and
granules for oral suspension.
The objective of this study was to evaluate and compare the relative bioavailability, and
therefore the bioequivalence of Clarithromycin 500 mg test formulation versus a reference Klacid®
forte 500 mg formulation, following a single dose administration under fasting conditions.
The study was a single center, open, single dose, randomized, two-way crossover study in
healthy male volunteers, with a wash-out period of one week between study periods. Twenty-four
male healthy volunteers, aged 18-49 years were included into study. Blood samples for
determination of clarithromycin and 14-OH clarithromycin concentrations were withdrawn at zero
(pre-drug administration), 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 and 36 hours post-drug
administration.
The determination of clarithromycin and 14-OH clarithromycin concentrations in plasma
was performed using validated LC/MS/MS method and internal standardization after liquid/liquid
extraction with methyl t-butyl ether.
The test formulation of clarithromycin, dosed at 500 mg is bioequivalent for primary
clarithromycin and 14-OH clarithromycin parameters (Cmax, AUC0-t and AUC0-∞) to the reference
formulation after a single oral administration of 500 mg clarithromycin. Both medications were
well tolerated with no serious adverse events. Thus, in view of the clinical use, both formulations
are exchangeable without restrictions.
File(s)![Thumbnail Image]()
Loading...
Name
65_1_002.pdf
Size
678.67 KB
Format
Adobe PDF
Checksum
(MD5):98aa5dad28b7e3ec32fb90fbfd0bc7b0